Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.47 |
| ▸ | CA1 | P00915 | 4/20 | 0.47 |
| ▸ | CA9 | Q16790 | 4/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | CA7 | P43166 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | STAT3 | P40763 | 2/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 3/20 | 0.40 |
| ▸ | MMP13 | P45452 | 2/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2545096 | 1.00 | CA2 (0.47) | CA2CA1CA9CA4CA7 | |
| SCHEMBL2545093 | 1.00 | CA2 (0.47) | CA2CA1CA9CA4CA7 | |
| SCHEMBL10569435 | 0.88 | CA2 (0.54) | CA2CA1CA9CA4CA7 | |
| SCHEMBL4342914 | 0.88 | CA2 (0.46) | CA2CA1CA9CA4CA7 | |
| SCHEMBL25320652 | 0.85 | ALDH1A1 (0.46) | CA2CA1CA9CA4CA7 | |
| SCHEMBL15627953 | 0.85 | AAK1 (0.52) | CA2CA1CA9CA4CA7 | |
| SCHEMBL25320649 | 0.85 | ALDH1A1 (0.46) | CA2CA1CA9CA4CA7 | |
| SCHEMBL3113962 | 0.85 | ALDH1A1 (0.55) | CA2CA1CA9CA4CA7 | |
| SCHEMBL8193095 | 0.85 | ALDH1A1 (0.43) | CA2CA1CA9CA4CA7 | |
| SCHEMBL26118690 | 0.85 | ALDH1A1 (0.55) | CA2CA1CA9CA4CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022262671-A1 | MACRO HETEROCYCLIC COMPOUND AND MEDICAL USE THEREOF | 中国医药研究开发中心有限公司 | 2022-12-22 | — | — | WO | disclosed |
| US-20210087206-A1 | MACROCYCLIC KINASE INHIBITORS AND THEIR USE | TURNING POINT THERAPEUTICS INC (US) | 2021-03-25 | — | — | US | disclosed |
| US-20150344485-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| US-20150344485-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2015-12-03 | — | — | US | disclosed |
| WO-2007072041-A1 | THERAPEUTIC COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2007-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150344485-A1 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 | PLA2G4A, PLA2G7, PLA2G6 | CA2 3372/4885CA1 3522/4885CA9 4371/4885 |
| US-20210087206-A1 | MACROCYCLIC KINASE INHIBITORS AND THEIR USE | MAP3K20, LCK, MAP3K1 | CA2 1550/4885CA1 2123/4885CA9 2515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.